**5. Conclusions**

The continued discovery of novel, biologically active bacterial metabolites is required to address the need for antimicrobials and anticancer therapeutics. Assessment of biosynthetic space within the growing amount of genome data from myxobacteria can provide insight to direct responsible discovery efforts [72–75]. This survey likely underestimates the unexplored biosynthetic space from myxobacteria. However, the vast discrepancies between BGCs with and without sequence similarity to characterized pathways suggests continued discovery of novel metabolites from this subset of 36 myxobacteria and exemplifies the outstanding potential associated with the Myxococcales at large.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2076-2607/7/6/181/s1. Supplemental Figure S1, annotated .cys file for all BGCs, and annotated .cys file for Other type BGCs.

**Author Contributions:** Conceptualization, supervision, and administration, D.C.S.; methodology, formal analysis, data curation, and validation, K.G., L.A.S., and D.C.S.; writing, K.G., L.A.S., S.A., B.I.A., and D.C.S.

**Funding:** This research was funded by the American Association of Colleges of Pharmacy New Investigator Award (D.C.S.), and salary support was provided for S.A. and D.C.S. by the National Cancer Institute (1R03CA219320-01A1).

**Acknowledgments:** The authors would like to acknowledge the University of Mississippi School of Pharmacy for startup support and the Sally Barksdale Honors College for encouraging undergraduate research.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
